SXR-1096

DB18119InvestigationalSmall molecule

SXR-1096: Overview.

Mechanism: Pharmacologically active on Kallikrein-7, Kallikrein-5, and Kallikrein-14
Curator reviewed
Formula / weight: C₁₈H₁₇NO₄S · 343.4 g/mol (avg)
Also known as: 4h-3,1-benzoxazin-4-one, 6-ethoxy-7-methoxy-2-(2-(methylthio)phenyl)- · 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one
Code names: SXR-1096

Resolves to

Compound

Structure

InChIKeyJTQBMTFVGGUDPN-UHFFFAOYSA-NSMILESCCOC1=C(OC)C=C2N=C(OC(=O)C2=C1)C1=CC=CC=C1SC

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with SXR-1096, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.